Skip to content
FDA-approved (Vyleesi)For Wet✓ Free to read

PT-141

Also called Bremelanotide / Vyleesi

An FDA-approved shot that works on sexual desire in the brain. It boosts wanting it, not the ability to perform.

Updated 19 May 2026Read 4 minBacked by 60 studies
The quick version
What it is
A brain-acting peptide for low sexual desire (brand name Vyleesi)
Is it FDA-approved?
Yes, for low desire in premenopausal women. All other use is off-label
How strong is the proof?
Strong for that one group. Two large Phase 3 trials
How you take it
A small shot before you want the effect, not every day
Typical result
A real but modest rise in desire. Not a sure thing
Biggest catch
About 40% feel nausea. It raises blood pressure for a few hours

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

PT-141 is a that acts in the brain. Its other name is bremelanotide. The brand is Vyleesi.

It works on the brain's desire system. It does not work on the plumbing. So it can raise the wish for sex. It does not, by itself, create an erection.

It came out of the same university program as the tanning Melanotan II. But PT-141 does not give a strong tan.

It is . The U.S. government checked it in large studies and agreed it works for one specific group of women.

What people use it for.

It is for low sexual desire. The exact approved use is for premenopausal women with low desire that bothers them. Doctors call that HSDD.

Some men and some postmenopausal women use it too, but that is off-label. Off-label means a doctor can prescribe it for that, but it was not approved or trial-tested for that group.

One thing to be clear about. If the problem is that you want sex but cannot perform, PT-141 is the wrong tool. That is an erection problem. A drug like sildenafil (Viagra) fits that. PT-141 is for the "I just do not want to" problem.

Does it actually work?

Yes, for the right person, but the effect is modest.

Two large Phase 3 trials (called RECONNECT) tested it in 1,247 premenopausal women with low desire. Desire scores went up and distress went down compared to a fake shot. That result is real.

But "real" is not the same as "magic." The boost is modest. This is not a guaranteed great night. And for men, the proof is weaker. Their use leans on how the drug works plus user reports, not on a big trial of their own.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

It's the female Viagra.

half true

Viagra works on the plumbing. PT-141 works on the wanting, in the brain. It can raise desire but it does not, by itself, create an erection or arousal blood flow.

It gives men rock-hard erections.

not quite

It is built for low desire, not for performance. For men the use is off-label and the proof leans on user reports, not a big trial. If you can want sex but cannot perform, an erection drug fits better.

A clean, natural aphrodisiac with no side effects.

no

About 40% of women in the trials felt real nausea, the top reason people quit. It also pushes blood pressure up for several hours, so it is not a free ride.

One shot and you're guaranteed an incredible night.

overblown

The trials are real but the boost is modest. Desire went up versus a fake shot, not to a sure thing. Treat it as a nudge, not a switch.

Research PT-141 is the same stuff as the prescription version.

no

"PT-141" sometimes tests as Melanotan II, a different from the same program. A strong tan, darkening moles, and heavy nausea mean you got the wrong molecule.

How you take it.

You take it as a small shot under the skin, about 45 minutes before the time you want the effect. It is on-demand, not a daily medicine.

The brand dose is 1.75 mg, given by an auto-injector. The rule is no more than one dose in 24 hours, and no more than 8 doses a month.

Smart tip: take your first dose at home, not out at a bar or hotel. About 4 in 10 people feel real nausea. You want to know how your body reacts in a safe spot first.

What to watch out for.

The common stuff

Nausea is the big one. About 40% of women in the trials felt it. It is the top reason people quit.

The serious stuff

  • It raises blood pressure for a while. Peak is about +6 points on the top number, lasting around 12 hours. Skip it if you have uncontrolled high blood pressure or heart disease.
  • Do not mix it at full dose with erection drugs like sildenafil or tadalafil. Both can move blood pressure, and stacking them is risky. The label warns against this. If you need both, that is a doctor talk.
  • If you have a personal or family history of melanoma (a skin cancer), be careful. It is in the same family as the tanning peptides.

Talk to a real doctor, ideally one who can check your blood pressure. We are not your doctor.

Where people get it.

Here are the ways people get it, from safest to riskiest.

  • Brand (Vyleesi). The real, auto-injector. About $290 a dose, or $900 to $1,000 for a 4-pack. Only on-label lane, and only for the approved group of women. Safest.
  • . Made by special pharmacies, often through telehealth or men's-health clinics. About $80 to $300 a month, as a nasal spray or a shot. This is the main off-label lane and is pharmacy-grade.
  • Research-only (). Cheap, about $30 to $70 a month, sold "for research only." Highest risk here.
  • . Overseas powder, very cheap. Illegal to import for human use.

The scam to know about: "PT-141" is sometimes really Melanotan II, a different from the same program. The tell is a strong tan, darkening moles, and heavy nausea. If you see that, you got the wrong molecule. Stop and switch sellers.

Our honest take.

Viagra fixes the plumbing. This fixes the wanting
For a premenopausal woman whose low desire genuinely bothers her, this is the one drug built for exactly that problem, and it works. Not magic, but real. Get it as Vyleesi through a women's-health doctor.

The catch lives in the timing. About 4 in 10 people get queasy, and you dose it roughly 45 minutes before sex, so the wrong reaction shows up at the worst possible moment. That is why a first try belongs at home, not a hotel.

For men and postmenopausal women this is off-label, and the route through a clinic with a blood-pressure cuff in the room is the sane version. The vial to avoid is the one, where "PT-141" sometimes turns out to be Melanotan and the blood-pressure hit is anyone's guess. And erection pills do not belong in the same full dose without a doctor in the loop.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Hedlund P. PT-141 Palatin. Current opinion in investigational drugs (London, England : 2000). 2004;5(4):456-62. PMID: 15134289.
  2. 02Nappi RE, et al. Medical Treatment of Female Sexual Dysfunction. The Urologic clinics of North America. 2022;49(2):299-307. PMID: 35428435.
  3. 03 Bremelanotide. 2021. PMID: 34436837.
  4. 04 Bremelanotide. 2025. PMID: 31369224.
  5. 05Dhillon S, et al. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. PMID: 31429064.
  6. 06Pettigrew JA, et al. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. Journal of midwifery & women's health. 2021;66(6):740-748. PMID: 34510696.
  7. 07Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. The journal of sexual medicine. 2006;3(4):628-638. PMID: 16839319.
  8. 08Sweeney P, et al. Targeting the central melanocortin system for the treatment of metabolic disorders. Nature reviews. Endocrinology. 2023;19(9):507-519. PMID: 37365323.
  9. 09Edinoff AN, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international. 2022;14(1):75-88. PMID: 35076581.
  10. 10Mayer D, et al. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. The Annals of pharmacotherapy. 2020;54(7):684-690. PMID: 31893927.
  11. 11Spielmans GI, et al. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research. 2024;61(4):540-561. PMID: 36809187.
  12. 12Clayton AH, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002). 2022;31(2):171-182. PMID: 35147466.
  13. 13Spielmans GI. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research. 2021;58(9):1085-1105. PMID: 33678061.
  14. 14Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and gynecology. 2019;134(5):899-908. PMID: 31599840.
  15. 15Cipriani S, et al. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy. 2023;24(1):15-21. PMID: 36242769.
  16. 16Pfaus JG, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums. 2022;27(3):281-289. PMID: 33455598.
  17. 17Mintzes B, et al. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin. 2021;59(12):185-188. PMID: 34642243.
  18. 18Simon JA, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002). 2022;31(3):391-400. PMID: 35230162.
  19. 19Lee JH, et al. Pharmacotherapy for Sexual Dysfunction in Women. Current psychiatry reports. 2022;24(2):99-109. PMID: 35102537.
  20. 20How A, et al. Novel Pharmacologic Treatments of Female Sexual Dysfunction. Clinical obstetrics and gynecology. 2025;68(1):10-14. PMID: 39846877.
  21. 21Burton CS, et al. Pharmacologic therapeutic options for sexual dysfunction. Current opinion in obstetrics & gynecology. 2022;34(6):402-408. PMID: 36036468.
  22. 22Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003;994:96-102. PMID: 12851303.
  23. 23 Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. The Medical letter on drugs and therapeutics. 2019;61(1577):114-116. PMID: 31381550.
  24. 24Althof S, et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. The journal of sexual medicine. 2019;16(8):1226-1235. PMID: 31277966.
  25. 25Shadiack AM, et al. Melanocortins in the treatment of male and female sexual dysfunction. Current topics in medicinal chemistry. 2007;7(11):1137-44. PMID: 17584134.
  26. 26 Bremelanotide: the female Viagra?. Expert review of endocrinology & metabolism. 2006;1(4):465-466. PMID: 30290453.
  27. 27Petherick A. Sexual arousal: Sex matters. Nature. 2017;550(7674):S2-S3. PMID: 28976951.
  28. 28Hussar DA. New Drugs 2020, part 2. Nursing. 2020;50(5):31-40. PMID: 32332502.
  29. 29Suzuki S, et al. Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression. Anticancer research. 2024;44(9):3875-3883. PMID: 39197897.
  30. 30Spana C, et al. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, obesity & metabolism. 2022;24(6):1084-1093. PMID: 35170192.
  31. 31Bardhan M, et al. Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases. Diseases (Basel, Switzerland). 2025;13(9). PMID: 41002740.
  32. 32Zhong Q, et al. Management of Hypertension with Female Sexual Dysfunction. Medicina (Kaunas, Lithuania). 2022;58(5). PMID: 35630054.
  33. 33Toledo RG, et al. Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options. Journal of minimally invasive gynecology. 2026;33(1):16-33.e3. PMID: 40543759.
  34. 34Barakeh D, et al. Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. The Annals of pharmacotherapy. 2025;59(2):148-161. PMID: 38767282.
  35. 35Kim NN. Finding Our Way From the Bench to the Bedside: The Ethos, Logos, and Pathos of Biomedical Research. Sexual medicine reviews. 2022;10(3):353-359. PMID: 35772848.
  36. 36Bridges TM. Pharmaceutical aphrodisia. Current topics in medicinal chemistry. 2007;7(11):1152. PMID: 17722370.
  37. 37Ila V, et al. Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions. Expert opinion on pharmacotherapy. 2025;26(5):631-637. PMID: 40069591.
  38. 38Al Shaer D, et al. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel, Switzerland). 2020;13(3). PMID: 32151051.
  39. 39Safarinejad MR, et al. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of urology. 2008;179(3):1066-71. PMID: 18206919.
  40. 40Pfaus J, et al. Bremelanotide: an overview of preclinical CNS effects on female sexual function. The journal of sexual medicine. 2007;4 Suppl 4:269-79. PMID: 17958619.
  41. 41Yuan XC, et al. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Biomolecules. 2022;12(10). PMID: 36291616.
  42. 42Fuhrman J, et al. Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies. Expert review of clinical pharmacology. 2025;18(10):1-13. PMID: 41088800.
  43. 43Krupke H, et al. A biodegradable suction patch for sustainable transbuccal peptide delivery. Journal of controlled release : official journal of the Controlled Release Society. 2025;384:113947. PMID: 40513668.
  44. 44Carson SA. Boosting Female Sexual Response by RECONNECTing the Dots. Obstetrics and gynecology. 2019;134(5):897-898. PMID: 31599837.
  45. 45Koochaki P, et al. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. Journal of women's health (2002). 2021;30(4):587-595. PMID: 33538638.
  46. 46Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and gynecology. 2019;134(5):909-917. PMID: 31599847.
  47. 47Hadley ME, et al. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-30. PMID: 16412534.
  48. 48Diamond LE, et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755-9. PMID: 15833522.
  49. 49Giliberto S, et al. A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022). Cureus. 2024;16(3):e56561. PMID: 38646400.
  50. 50Gelman F, et al. Flibanserin for hypoactive sexual desire disorder: place in therapy. Therapeutic advances in chronic disease. 2017;8(1):16-25. PMID: 28203348.
  51. 51Both S. Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder. Current sexual health reports. 2017;9(4):192-199. PMID: 29225554.
  52. 52Rosen RC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International journal of impotence research. 2004;16(2):135-42. PMID: 14999221.
  53. 53Borland JM, et al. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;267:110299. PMID: 39793696.
  54. 54Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's health (London, England). 2016;12(3):325-37. PMID: 27181790.
  55. 55Hellstrom WJ. Clinical applications of centrally acting agents in male sexual dysfunction. International journal of impotence research. 2008;20 Suppl 1:S17-23. PMID: 18552830.
  56. 56da Silva Lara LA, et al. Female sexual dysfunctions: an overview on the available therapeutic interventions. Minerva obstetrics and gynecology. 2022;74(3):249-260. PMID: 35147017.
  57. 57Sauter M, et al. Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. Journal of pharmaceutical and biomedical analysis. 2020;186:113276. PMID: 32353679.
  58. 58Clayton AH, et al. Evaluation and Management of Hypoactive Sexual Desire Disorder. Sexual medicine. 2018;6(2):59-74. PMID: 29523488.
  59. 59Ronghe V, et al. Understanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment. Cureus. 2023;15(11):e49690. PMID: 38161863.
  60. 60Shadiack AM, et al. Preclinical effects of melanocortins in male sexual dysfunction. International journal of impotence research. 2008;20 Suppl 1:S11-6. PMID: 18552829.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.